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 Familial hypercholesterolaemia (FH) is a common ge-
netic disorder that causes elevated levels of atherogenic 
lipoproteins in the plasma, particularly LDL cholesterol. 
Over 85% of FH cases are caused by mutations in the LDL 
receptor rendering these receptors unable to bind or in-
ternalize LDL and leading to accumulation in the plasma 
( 1 ). The disease follows an autosomal dominant pattern 
of inheritance and can result in heterozygote or more 
serious homozygote forms ( 2 ). In severe forms of FH, diet 
alteration and lipid lowering medications are often insuf-
fi cient to lower LDL levels enough to abate atherosclerotic 
plaque formation ( 3 ). These patients therefore require 
frequent (bi-weekly) lipoprotein-apheresis (hereafter re-
ferred to as “apheresis”) treatments in combination with 
dietary and pharmacological intervention to control LDL 
levels ( 4 ). 
 Apheresis is a safe well-established procedure for the ex-
tracorporeal removal of LDL. Blood is removed from one 
arm and passed through a column to remove atherogenic 
lipoproteins before being returned to the body via the other 
arm. Different apheresis techniques may be utilized, but all 
reduce LDL by approximately 70% immediately following 
 Abstract  Lipoprotein-apheresis (apheresis) removes LDL-
cholesterol in patients with severe dyslipidemia. However, 
reduction is transient, indicating that the long-term cardio-
vascular benefi ts of apheresis may not solely be due to 
LDL removal. Microparticles (MPs) are submicron vesicles 
released from the plasma membrane of cells. MPs, partic-
ularly platelet-derived MPs, are increasingly being linked 
to the pathogenesis of many diseases. We aimed to charac-
terize the effect of apheresis on MP size, concentration, 
cellular origin, and fatty acid concentration in individuals 
with familial hypercholesterolemia (FH). Plasma and MP 
samples were collected from 12 individuals with FH under-
going routine apheresis. Tunable resistive pulse sensing 
(np200) and nanoparticle tracking analysis measured a fall 
in MP concentration (33 and 15%, respectively;  P < 0.05) 
pre- to post-apheresis. Flow cytometry showed MPs were 
predominantly annexin V positive and of platelet (CD41) 
origin both pre- (88.9%) and post-apheresis (88.4%). Fatty 
acid composition of MPs differed from that of plasma, 
though apheresis affected a similar profi le of fatty acids in 
both compartments, as measured by GC-fl ame ionization 
detection. MP concentration was also shown to positively 
correlate with thrombin generation potential.  In conclu-
sion, we show apheresis nonselectively removes annexin 
V-positive platelet-derived MPs in individuals with FH. 
These MPs are potent inducers of coagulation and are el-
evated in CVD; this reduction in pathological MPs could 
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For clinical reasons patients underwent treatment using three 
different techniques: polyacrylate whole blood adsorption 
(DALI®; n = 8), whole blood dextran sulfate adsorption (n = 1), 
or plasma dextran sulfate adsorption (n = 3), as described previ-
ously ( 24 ). Patients attended the Lipid Unit at University Hospi-
tal Llandough, Cardiff for apheresis treatment as part of their 
normal clinical care. Patients fasted for at least 4 h prior to at-
tendance and took their prescribed medication for at least 1 h 
prior to the study, excluding vasoactive medications from which 
patients were asked to refrain. Routine anthropometric mea-
surements were carried out prior to apheresis treatment. After 
15 min of rest, vascular access was gained using 16 gauge 25 mm 
fi stula needles into two anatomically distinct upper limb veins or 
by arteriovenous fi stula. Blood samples were then drawn sequen-
tially prior to and immediately after completion of apheresis, 
approximately 3 h later. Seven healthy volunteers (free of CVD 
and medication) were also recruited to the study to compare MP 
concentration, size distribution, cellular origin, and fatty acid 
profi le with FH individuals. Ethical approval for obtaining blood 
samples was provided by the South East Wales Research Ethics 
Committee. 
 Biochemical measurements 
 Blood samples were collected as described above into EDTA 
and citrate vacutainers. An Architect automated analyzer (Abbott 
Diagnostics, Berkshire, UK) was used to measure total serum cho-
lesterol (TC), HDL, and triglycerides; LDL was then estimated 
using the Friedewald equation. Glucose levels were determined by 
using the Architect chemistry system (Abbott Diagnostics) and 
high sensitivity C-reactive protein (hsCRP) was measured using 
nephelometry (BN™ II system, Dade Behring, UK). Blood pres-
sure (BP) measurements were taken with patients seated using 
the Vicorder system (Skidmore Medical, UK) as part of a separate 
study. 
 MP isolation 
 Blood, collected as above, was immediately centrifuged (1,509  g , 
10 min, 4°C) to obtain platelet-poor plasma (PPP). EDTA plasma 
was snap-frozen in liquid nitrogen. Citrate plasma was ultracen-
trifuged (100,000  g , 1 h, 4°C) and the MP pellet was resuspended 
in either PBS and snap-frozen, in liquid nitrogen (for GC analy-
sis), or in PBS containing 0.05% (v/v) Tween 20 (for MP size and 
concentration). The latter was then passed through a 1   m fi lter 
(Supelco, Sigma-Aldrich, UK) and slow-frozen overnight at 
  80°C in a Mr Frosty (Nalgene, Thermo Scientifi c, UK). Plasma 
and MPs were maintained at   80°C until analysis. 
 MP size and concentration 
 Two techniques were used to measure MP size and concentra-
tion: tunable resistive pulse sensing (TRPS) and nanoparticle 
tracking analysis (NTA). TRPS was carried out using the qNano 
(Izon Science, New Zealand), which uses an electrophoresis-
based method to determine the size and concentration of MPs 
on a particle-by-particle basis. Particles pass through a tunable 
nanopore which detects particles within a specifi c size range. 
Therefore, in order to analyze MP size and concentration across 
a full spectrum, nanopore 100 (np100) and nanopore 200 
(np200) were used. NTA was undertaken using the NanoSight 
LM10 (NanoSight Ltd., UK) with settings as previously described 
( 25 ) using the NTA software (version 2.3). NTA uses the light 
scattering by MPs and tracks their Brownian motion in suspen-
sion over time to relate this to MP size and concentration. Sixty 
second videos were recorded in replicates of fi ve per sample with 
camera sensitivity and detection threshold set to 14–16 and 5–6, 
respectively. 
treatment ( 5–9 ). However, posttreatment LDL levels are 
not maintained, with levels rising to 50% of pretreatment 
values within 2–4 days ( 10 ). Despite this transiency, apher-
esis is associated with superior long-term cardiovascular 
benefi ts compared with alternative therapies ( 11–15 ). 
 Microparticles (MPs) are heterogeneous submicron vesi-
cles released from many different cell types. Several terms 
exist to describe these vesicles, though here we use “MPs” as 
an umbrella term to encompass vesicles ranging from 
30 nm to 1   m in diameter. This range includes both exo-
somes and microvesicles. Exosomes are classically 30–100 
nm in size and are produced from intracellular processing 
of endocytosed material, which is then incorporated into 
exosomes and released from the cell by exocytosis. Mi-
crovesicles are vesicles ranging from 100 nm to 1   m re-
leased directly from the plasma membrane of cells in 
response to cellular activation or apoptosis. The phospho-
lipid asymmetry of the cells’ plasma membrane is disrupted 
and, consequently, phosphatidylserine (PS) is externalized 
to the outer membrane. This is commonly used to identify 
microvesicle populations via annexin V binding. MPs are 
released both in vivo and in vitro into the external environ-
ment of many cell types, allowing subsequent isolation from 
biological fl uids or conditioned culture media ( 16 ). 
 Increased numbers of MPs, particularly those derived 
from platelets, have been reported in many CVDs ( 17, 18 ), 
though their function in both health and disease remains 
poorly understood. The surface of platelet MPs is report-
edly up to 100-fold more procoagulant than that of acti-
vated platelets due to an increased density of PS, P-selectin, 
and factor X ( 19 ). Furthermore, MPs are known to carry 
specifi c mRNAs, microRNAs, proteins, and lipid signaling 
molecules. These bioactive entities are thought to be deliv-
ered to target cells, though the mechanism by which this 
interaction occurs is still unknown ( 20 ). To date, little is 
known about the lipid concentration and profi le of MPs, 
though platelet MPs have been shown to transfer pro-in-
fl ammatory lipids to platelets leading to activation ( 20 ). 
 Heterozygous FH patients have previously been shown 
to have increased circulating levels of endothelial- and 
leukocyte-derived MPs compared with nonFH patients 
( 21 ). However, quantifi cation of MPs in this study was 
achieved using fl ow cytometry, which is not considered op-
timal due to the technique’s lack of sensitivity for particles 
<200 nm. To our knowledge, no data exist detailing the 
effects of apheresis on MPs in individuals with FH, though 
other extracorporeal methods have been previously shown 
to remove MPs ( 22, 23 ). 
 Here we aimed to characterize size, concentration, cellu-
lar origin, fatty acids, and thrombin generation of MPs in 
FH patients undergoing apheresis, hypothesizing that this 
treatment would reduce circulating MPs as well as LDL. 
 METHODS 
 Patients 
 Twelve patients with clinically signifi cant dyslipidemia under-
going fortnightly apheresis consented to take part in the study. 
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96-well plates (round-bottomed, Immulon 2HB, Thermo Scien-
tifi c). Eighty microliters of vehicle PPP (containing endogenous 
clotting factors) were added to each well with 20   l of diluted 
HEPES/NaCl buffer (pH 7.4) tissue factor (TF) solution to yield 
a fi nal concentration of 1 pM (Innovin, Sysmex UK Ltd., UK). 
FH MP samples were assayed for thrombin generation both with 
and without exogenous TF addition. Therefore, MPs (20   l) 
were added to sample wells with the addition of either saline 
(20   l, 0.9% NaCl) or TF (20   l, 1 pM fi nal). Each sample was 
calibrated to a well containing 80   l of PPP and 40   l of throm-
bin calibrator (600 nM, Synapse BV, The Netherlands). The 
plate was then warmed to 37°C for 5 min before addition of fl uo-
rogenic substrate (20   l, Z-Gly-Gly-Arg-AMC, Bachem, UK). The 
fl uorescent signal was then measured using a Fluoroskan Ascent 
plate reader (ThermoLabsystems, Finland) equipped with a 
390/460 nm fi lter set (excitation/emission) at 15 s intervals until 
the thrombin generation reaction was complete. Data were ana-
lyzed using Thrombinoscope™ software (Synapse BV, The Neth-
erlands) and correlated with MP concentration data. 
 Statistical analysis 
 Data are presented as mean ± SEM. A paired  t -test (two-tailed) 
or a Wilcoxon matched pairs test was used for parametric and 
nonparametric data, respectively. Analyses were conducted using 
GraphPad Prism (version 6; GraphPad Software Inc., CA) and 
 P < 0.05 was considered statistically signifi cant. 
 RESULTS 
 Anthropometric and biochemical data 
 Of the 12 participants in the study, 9 were male and 3 
female with a mean age of 57.9 ± 10.3 years and a mean 
BMI of 30.0 ± 4.0 kg/m 2 . Biochemical measurements are 
summarized in  Table 1 . Apheresis reduced TC, triglycer-
ides, HDL, LDL hsCRP, and systolic BP. No changes were 
observed in glucose levels, diastolic BP, or heart rate. 
 MP size and concentration pre- versus post-apheresis 
 Two techniques, TRPS (using np100 and np200) and 
NTA, were used to analyze MP size and concentration; 
therefore, the detectability was compared for each tech-
nique pre- and post-apheresis (supplementary Fig. IA, B). 
The size distribution of MPs was similar for TRPS (np100 
and np200) and NTA, though the measured concentration 
varied greatly between the two techniques. Mode size of 
MPs did not change following apheresis by any technique 
 MP origin 
 Flow cytometry was used to determine MP origin using a cus-
tom-built BD FACSAria II (BD Biosciences, CA). Forward scatter 
area (FSC-A) and side scatter area (SSC-A) were set to log scale 
and MPs were gated based on their FSC-A/SSC-A profi le and in 
relation to platelets in fresh plasma. MP pellets were resuspended 
in 1× 0.22   m-fi ltered annexin V binding buffer (BD Biosci-
ences) and 100   l of this was used for staining. MPs were stained 
in the dark (15 min, room temperature ) with annexin V-FITC 
(1.57   g/ml), CD41-PE-Cy5 (0.12   g/ml), CD11b-PE-Cy7 
(7.9   g/ml), CD144-APC (4.1   g/ml), and CD235a-PB (7.7   g/ml) 
as markers of MPs, platelets, monocytes, endothelial cells, and 
erythrocytes, respectively (all antibodies from BioLegend, CA). 
Data were exported from the FACSDiva™ software (version 6) 
and subsequently analyzed in FlowJo software (version 9.6.4; 
Tree Star Inc., OR). 
 MP fatty acid profi le 
 Fatty acid profi les were analyzed using GC-fl ame ionization de-
tection (FID) as described previously ( 26 ). Briefl y, lipids were 
extracted from 200   l of plasma or isolated MP samples (250   l) 
with chloroform:methanol (1:2, v/v) by the method of Garbus 
et al. ( 27 ). Fatty acid methyl esters (FAMEs) were prepared by 
incubation for 2 h with 2.5% H 2 SO 4 in dry methanol:toluene 
(2:1, v/v) at 70°C. A known amount of C19:0 (nonadecylic acid; 
Nu-Chek Prep, Inc., Elysian, MN) was added as an internal stan-
dard, so that subsequent quantifi cation of peaks (and, conse-
quently, lipids) could be performed. FAMEs were analyzed by GC 
using a Clarus 500 gas chromatograph (Perkin-Elmer 8500, Nor-
walk, CT), fi tted with a 30 m × 0.25 mm inner diameter, 0.25   m 
fi lm thickness capillary column (Elite 225, Perkin-Elmer). The 
column temperature was held at 170°C for 3 min, and then tem-
perature-programmed to 220°C at 4°C/min. Nitrogen was the 
carrier gas at a fl ow rate 2 ml/min. FAMEs were identifi ed rou-
tinely by comparing retention times of peaks with those of stan-
dard (Supelco 37 Component FAME Mix, Sigma-Aldrich and 
Nu-Chek Prep, Inc.). Perkin-Elmer Total Chrom Navigator soft-
ware was used for data acquisition. 
 MP thrombin generation 
 To provide a working reservoir of plasma in which to test 
thrombin generation of MP, blood was drawn gently from healthy 
volunteers into a syringe containing 6 mM trisodium citrate 
(Sigma-Aldrich) and 20   g/ml corn trypsin inhibitor (Cam-
bridge BioScience, UK) and centrifuged (1,024  g , 10 min, 4°C) 
to yield “vehicle” PPP. Samples were then stored at   80°C until 
analysis. 
 To asses MP thrombin generation, calibrated automated 
thrombography was used, as described previously ( 28 ), with mi-
nor modifi cations. Samples were measured in duplicate using 
 TABLE 1. Biochemical and physiological measurements pre- and post-apheresis 
Pre-apheresis Post-apheresis Change (%)  P 
TC (mmol/l) 6.1 ± 0.5 2.7 ± 0.2   57.1 <0.0001 a 
HDL (mmol/l) 1.1 (0.4–2.3) 0.9 (0.2–2.1)   21.0 0.003 a 
Triglycerides (mmol/l) 1.8 ± 0.2 0.9 ± 0.1   50.0 <0.0001 a 
LDL (mmol/l) 4.1 ± 0.4 1.4 ± 0.2   66.1 <0.0001 a 
TC/HDL 5.8 (3.3–10.0) 3.1 (1.9–8.2)   41.9 0.0005 a 
Glucose (mmol/l) 5.7 ± 0.3 6.1 ± 0.3 8.4 0.07
hsCRP (mg/l) 0.8 (0.2–16.9) 0.6 (0.2–13.8)   29.8 0.003 a 
Systolic BP (mmHg) 140 ± 5 148 ± 6 6.5 0.02 a 
Diastolic BP (mmHg) 81.8 ± 2.8 82.8 ± 2.7 1.4 0.45
Heart rate (bpm) 55.8 ± 2.9 58.8 ± 3.4 5.8 0.09
Data are presented as mean ± SEM or median (range), n = 12. bpm, beats per minute.
 a Denotes statistical signifi cance
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and NTA, respectively ]. Total cholesterol was measured in 
the MP fraction and was below the detectability of the as-
say (<0.01 mmol/l). Size/concentration distributions of 
MPs are shown pre- to post-apheresis for each technique. 
TRPS (np100) and NTA show no preferential reduction 
according to MP size ( Fig. 1B and  Fig. 1F , respectively), 
whereas TRPS (np200) shows a reduction in MPs between 
200 and 249 nm ( Fig. 1D ,  P = 0.01). The type of apheresis 
received by patients was not shown to affect MP concentra-
tion (supplementary Table I); however, the study was not 
powered to measure this as an endpoint. Comparison of 
MPs in FH patients with those in healthy volunteers 
showed a trend (nonsignifi cant) toward an increase in 
[81.1 ± 19.6 nm to 78.4 ± 16.7 nm,  P = 0.3 for TRPS 
(np100); 170.3 ± 40.6 nm to 163.6 ± 29.2 nm,  P = 0.18 for 
TRPS (np200); and 93.3 ± 21 nm to 88.2 ± 14.7 nm,  P = 
0.32 for NTA]. TRPS (np100) measured no difference in 
concentration pre- to post-apheresis (4.6 × 10 11 particles/
ml ± 1.3 × 10 11 particles/ml to 3.1 × 10 11 particles/ml ± 1.0 × 
10 11 particles/ml,  P = 0.18;  Fig. 1A ). However, TRPS 
(np200) and NTA both measured a decrease in MPs pre- 
versus post-apheresis [4.7 × 10 10 particles/ml ± 8.8 × 10 9 
particles/ml to 3.1 × 10 10 particles/ml ± 5.6 × 10 9 parti-
cles/ml and 1.9 × 10 12 particles/ml ± 2.4 × 10 11 particles/
ml to 1.5 × 10 12 particles/ml ± 2.4 × 10 11 particles/ml,  P = 
0.013 and  P = 0.025;  Fig. 1C and  Fig. 1E for TRPS (np200) 
 Fig.  1. MP concentration and size distributions pre- and post-apheresis. MP size and concentration were 
measured in pre- and post-apheresis samples using TRPS (np100 and np200) and NTA. Mean concentration 
of MPs pre- and post-apheresis is shown for TRPS np100 (A), TRPS np200 (C), and NTA (E). Size/concentra-
tion distribution of MPs pre- and post-apheresis is shown for TRPS np100 (B), TRPS np200 (D), and NTA (F). 
Concentrations are given in particles/ml of plasma. Data are presented as mean ± SEM (n = 12). * P < 0.05. 
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total concentration; however, the size distribution showed 
individuals with FH had increased concentrations of MPs 
between 50 and 100 nm ( P < 0.05, supplementary Fig. IIA 
and supplementary Fig. IIB, respectively). 
 Effect of apheresis on MP origin 
 MPs falling within the MP gate ( Fig. 2A ) showed no 
change in apportion of annexin V positivity following 
apheresis ( Fig. 2B ). Of these annexin V-positive MPs, there 
were also no changes in the proportions derived from 
platelets (CD41), endothelial cells (CD144), monocytes 
(CD11b), or erythrocytes (CD235a) ( Fig. 2C ). MPs posi-
tive for both annexin V and CD41 accounted for the ma-
jority (  90%) of MPs measured. The same was also true 
for MPs in healthy volunteers, though there was a minor 
increase in the proportion of endothelial-derived MPs 
in individuals with FH compared with healthy volunteers 
( P = 0.03, supplementary Fig. III). The apportion of MPs 
showed no observable differences depending on the type 
of apheresis (supplementary Table I), though the study 
was not powered on this basis. 
 MP fatty acid concentration and profi le pre- versus post-
apheresis 
 Little is known about the lipid concentration of MPs, 
thus we sought to determine the fatty acid concentration 
and profi le of MPs compared with that of the correspond-
ing plasma and to observe the effect of apheresis. Total 
plasma fatty acid concentration decreased following 
apheresis (8.1 ± 1.3 mM to 4.6 ± 0.8 mM;  P = 0.01), though 
this was not mirrored in the MP fraction ( Fig. 3A and  Fig. 
3C , respectively). Five individual fatty acids were altered in 
the plasma following apheresis ( P < 0.05): C14:0 (myristic 
acid), C18:0 (steric acid), C18:1n7 ( cis -vaccenic acid), 
C20:5n3 (eicosapentaenoic acid), and C22:3n3 (docosatri-
enoic acid); the former three also being altered in the MP 
fraction ( P < 0.05,  Fig. 3B and  Fig. 3D , respectively). Inter-
estingly, comparison of the compartments, plasma and 
MPs, revealed 10 fatty acids differed in composition ( P < 
0.05) ( Table 2 ). This was true in pre- and post-apheresis 
samples; however, the 10 fatty acids were not the same. 
Comparing FH patients to healthy volunteers, both plasma 
and MP fatty acid concentration were elevated in individu-
als with FH ( P = 0.02 and  P = 0.01, supplementary Fig. IVA 
and supplementary Fig. IVC, respectively). Eight fatty ac-
ids were different in plasma and nine were different in 
MPs comparing healthy volunteers and individuals with 
FH ( P < 0.05, supplementary Fig. IVB and supplementary
 Fig. IVD, respectively), and apheresis had a similar effect on 
fatty acids in either compartment. This was consistent with 
all types of apheresis received (supplementary Table I). 
 MP thrombin generation 
 Thrombin generation of MPs was analyzed pre- to post-
apheresis and was also correlated with total MP concentra-
tions. No change was observed in MP peak thrombin 
generation pre- to post-apheresis (14.8 ± 2.9 nM to 16.6 ± 
4.1 nM,  P = 0.6). However, MP thrombin generation over 
time [area under the curve (AUC)] was positively corre-
lated with MP concentration measured by TRPS (np100) 
and NTA ( r = 0.626,  P = 0.001 and  r = 0.424,  P = 0.04, re-
spectively). Thrombin AUC showed no correlation with 
MP concentration measured by TRPS (np200). Further-
more, when TF was added to MPs (to exogenously initiate 
maximum thrombin generation), thrombin AUC no lon-
ger correlated with MP concentration. 
 DISCUSSION 
 Circulating MPs are reportedly elevated in a number of 
diseases, including in patients with severe hypercholester-
olemia ( 21, 29 ). The present study shows novel data re-
garding the effects of apheresis on MP size, concentration, 
 TABLE 2. Fatty acid composition of the plasma and MP fraction 
Fatty Acid
Pre-apheresis Post-apheresis
Plasma Composition (%) MP Composition (%)  P Plasma Composition (%) MP Composition (%)  P 
C14:0 0.6 ± 0.1 1.09 ± 0.1 0.04 a 0.9 ± 0.1 0.6 ± 0.07 0.008 a 
C14:1 0.04 ± 0.01 0.1 ± 0.02 0.006 a 0.06 ± 0.1 0.1 ± 0.08 0.4
C16:0 15.7 ± 3.2 27.3 ± 3.2 0.07 10.5 ± 3.9 25.1 ± 1.2 0.002 a 
C16:1n7 2.5 ± 0.6 3.4 ± 0.4 0.4 2.0 ± 0.8 4.6 ± 0.7 0.02 a 
C18:0 5.0 ± 0.8 8.2 ± 0.9 0.07 3.1 ± 1.3 10.6 ± 0.6 <0.001 a 
C18:1n9 15.0 ± 4.2 6.2 ± 3.3 0.04 a 10.1 ± 6.0 17.7 ± 5.4 0.4
C18:1n7 11.3 ± 4.2 32.5 ± 3.4 0.003 a 31.8 ± 7.0 17.4 ± 5.4 0.1
C18:2n6 22.2 ± 5.8 13.3 ± 1.7 0.03 a 14.0 ± 3.6 15.3 ± 1.2 0.7
C20:1 0.4 ± 0.1 0.3 ± 0.03 0.6 0.4 ± 0.06 0.4 ± 0.07 0.3
C20:2n6 1.7 ± 1.0 0.6 ± 0.09 0.2 1.5 ± 0.1 0.8 ± 0.09 <0.001 a 
C20:5n3 0.9 ± 0.2 0.7 ± 0.15 0.03 a 2.2 ± 0.4 0.9 ± 0.15 0.002 a 
C22:0 0.3 ± 0.05 0.14 ± 0.06 0.02 a 0.5 ± 0.07 0.14 ± 0.04 0.001 a 
C22:3n3 0.1 ± 0.03 0.15 ± 0.09 0.7 0.2 ± 0.04 0.02 ± 0.01 <0.001 a 
C22:3n6 0.4 ± 0.1 0.2 ± 0.1 0.09 0.9 ± 0.4 0.03 ± 0.03 0.004 a 
C22:5n3 0.2 ± 0.06 0.07 ± 0.04 0.04 a 0.2 ± 0.1 0.3 ± 0.3 0.8
C22:6n3 1.2 ± 0.2 1.1 ± 0.2 0.09 2.4 ± 0.6 1.2 ± 0.2 0.09
C24:0 0.07 ± 0.03 0.002 ± 0.002 0.009 a 0.2 ± 0.05 0.02 ± 0.02 0.003 a 
C24:1n9 0.9 ± 0.2 0.2 ± 0.1 0.006 a 1.6 ± 0.7 0.04 ± 0.02 0.08
Individual fatty acid composition of the plasma and MPs were directly compared in pre-apheresis and post-
apheresis samples. Data are presented as mean ± SEM (n = 12).
 a Denotes statistical signifi cance.
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 Fig.  2. MP origin following apheresis. MPs from pre- and post-apheresis samples were analyzed by fl ow cytom-
etry to determine cellular origin. FSC-A and SSC-A of platelets from fresh plasma were used to determine a 
submicron gate where only annexin V-positive MPs were analyzed. A: A representative dot blot of FSC-A versus 
SSC-A indicates the position of the MP gate (kept consistent for all samples). Samples were stained with an-
nexin V, CD41, CD144, CD235a, and CD11b (B) to identify the proportion derived from platelets, endothelial 
cells, erythrocytes, and monocytes, respectively (C). Data are presented as mean ± SEM (n = 12). 
origin, fatty acid concentration, and thrombin generation 
in patients with FH. Our data demonstrate that apheresis 
reduces circulating MP concentration, the majority of 
which are annexin V-positive MPs derived from platelets. 
 Several methods exist to measure MPs, though often the 
technique employed is heavily dictated by the research 
question and protocol, and each exhibits unique advan-
tages/limitations. Thus, we sought to employ two well-
established methods for MP measurement in order to cap-
ture the full spectrum of MP sizes. To our knowledge, 
TRPS and NTA have not previously been subjected to a 
direct comparison in biological samples. Our data illus-
trate that the range of detectability of TRPS (np100 and 
np200) and NTA are similar, and although they differ 
vastly in reported MP concentration, taken together there 
is considerable agreement . 
 No change was observed with TRPS or NTA in mode 
particle size pre- versus post-apheresis. TRPS using the 
np200 and NTA showed a fall in MP concentration pre- 
versus post-apheresis. MPs within the range of 200–250 nm 
were reduced the most pre- versus post-apheresis, which is 
much greater than the size of LDL particles ( 30 ), indicat-
ing that the techniques are measuring a reduction in MPs 
and not LDL . MP concentration did not fall when measured 
with TRPS using the np100. This further supports that the 
observed fall in MP concentration by the np200 and NTA 
was not due to either technique detecting LDL, as the par-
ticulate size of LDL lies within the sensitivity of the np100 
pore range. MPs were also shown to be elevated in the exo-
somal range in individuals with FH compared with healthy 
volunteers. Total MP concentration also appears elevated 
in individuals with FH, though this did not quite reach 
signifi cance. 
 Flow cytometric measurement of MPs revealed no 
changes in annexin V positivity or cellular origin following 
apheresis. In keeping with previous data ( 21, 31, 32 ), 
platelet-MP occupied the majority of the MP population 
(88.9 ± 13%). Taken together with the fall in MP concen-
tration, this would suggest that apheresis nonselectively 
removes MPs, the majority of which are annexin V positive 
and derived from platelets. These MPs have not only been 
shown to be elevated in a variety of disease states ( 33–38 ), 
but have also been shown to promote coagulation ( 19 ) 
and atherosclerotic plaque formation ( 39 ), and to be as-
sociated with atherothrombotic events ( 35 ). Nonselective 
removal of these MPs by apheresis may reduce the risk of 
thrombus formation by slowing the progression of ath-
erosclerotic lesions, thereby complementing the effect of 
 at CARDIFF UNIVERSITY, on M
arch 31, 2016
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2014/08/13/jlr.M049726.DC1
Supplemental Material can be found at:
2070 Journal of Lipid Research Volume 55, 2014
LDL removal. MPs in healthy volunteers were also found 
to be mainly annexin V positive and of platelet origin. It 
would appear that individuals with FH have a greater num-
ber of these circulating annexin V/platelet-positive MPs. 
Individuals with FH had a greater apportion of endothe-
lial-derived MPs, perhaps suggesting a greater level of en-
dothelial activation compared with healthy volunteers, 
although the percentage of the total was still low (<2%). 
 GC-FID was used to measure fatty acid concentration 
and composition in plasma and MPs. The relative athero-
protective mechanisms of unsaturated and polyunsatu-
rated fatty acids are well-documented ( 40 ), as are the data 
implicating saturated fatty acids in arterial wall lipid accu-
mulation and atherosclerotic plaque formation ( 41 ). MPs 
have been shown to carry a specifi c cargo of proteins, ge-
netic material and small molecules, including fatty acids 
( 42 ), that can initiate a pro-infl ammatory response in tar-
get cells ( 20 ). Here, total fatty acid concentration of 
plasma was decreased following apheresis, however MP 
fatty acid levels did not change following apheresis. Thus, 
although the overall number of MPs decreases pre- versus 
post-apheresis, the fatty acid concentration per MP re-
mains the same. Interestingly, apheresis seemed to affect 
individual fatty acids differently in plasma compared with 
the MP fraction; however, the physiological relevance of 
this remains to be elucidated. Furthermore, when plasma 
was directly compared with the MP fraction, the apportion 
of fatty acids was found to be different between compart-
ments. This suggests that the fatty acid composition of MPs 
is independent to that of surrounding plasma, a concept 
we have previously found in a separate cohort of patients 
with polycystic ovary syndrome (unpublished observa-
tions). Several fatty acids were different in individuals with 
FH compared with healthy volunteers in both plasma and 
MPs, however, affected fatty acids and the trends (i.e., in-
crease or decrease) were the same. Similarly to the fi nd-
ings in FH, in healthy volunteers the fatty acid composition 
of MPs did not refl ect that of plasma. 
 The potential of MPs to generate thrombin was assessed 
using calibrated automated thrombography. No change 
was observed in MP peak thrombin generation pre- versus 
post-apheresis. However, total MP concentration mea-
sured by either TRPS (np100) or NTA showed a positive 
correlation with the total thrombin AUC, whereas MP con-
centration measured by TRPS (np200) showed no correla-
tion. Taken together, this suggests a reduction in MPs is 
associated with decreased thrombin generation capacity 
and that smaller MPs, particularly exosomes, are associ-
ated with an increased total thrombin generation over 
time. We conclude this on the basis that both TRPS 
(np100) and NTA have an increased sensitivity for MPs in 
the exosomal range compared with TRPS (np200) (sup-
plementary Fig. I). Furthermore, individuals with FH were 
shown to have an increased circulating population of 
 Fig.  3. GC-FID analysis of MPs following apheresis. Total fatty acid concentration of plasma and MPs (A and C, respectively) followed by 
fatty acid profi ling to determine compositional changes pre- to post-apheresis (B and D, respectively). Data are presented as mean ± SEM 
(n = 12). * P < 0.05, ** P < 0.01. 
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smaller MPs compared with healthy individuals (supple-
mentary Fig. II). Both TRPS (np100) and NTA showed a 
trend toward reduction in exosomal populations of MPs 
following apheresis ( Fig. 1B and  Fig. 1F , respectively), 
though this did not reach signifi cance. This could suggest 
that the increased circulating population of exosomes in 
individuals with FH makes their MP fraction more proco-
agulant. Apheresis treatment nonselectively removes MPs 
and could potentially reduce the procoagulant potential 
of exosomes and smaller MPs. Our results confi rm that 
MPs have endogenous TF activity and can stimulate throm-
bin generation, a fi nding in keeping with previous re-
search ( 43, 44 ). When exogenous TF was added to MPs to 
stimulate thrombin generation, the correlation between 
MP concentration and AUC was lost, refl ecting maximum 
thrombin generation. 
 Patients in this study received apheresis based on indi-
vidual clinical requirements resulting in the use of three 
different types of apheresis treatment. Though there was no 
observable difference between apheresis technique and MP 
concentration (supplementary Table I), the current study 
was not designed to assess this. In vitro studies have shown 
the surface morphology of the adsorbent polymer may af-
fect MP production ( 45 ), though this requires confi rmation 
in vivo. FH patients were studied as part of their routine 
clinical outpatient treatment. Clearly, having now estab-
lished that apheresis directly infl uences MP concentration, 
longitudinal studies will help to establish whether the re-
duction in atherogenic MPs is maintained while further ex-
ploring the physiological relevance this reduction in MPs 
has in regard to CVD pathology. The thrombin generation 
of patient MP samples was measured in the presence of 
pooled healthy plasma to specifi cally test the activity of MPs 
as opposed to whole patient plasma (that would likely re-
fl ect the total infl uence of apheresis). Future studies should 
assess the procoagulant activity of plasma pre- to post-apher-
esis to confi rm this reduction in atherogenic MPs. Finally, 
annexin V binding was used to classify MP populations for 
identifi cation of cellular origin using fl ow cytometry. It is 
acknowledged that many fl ow cytometers have a practical 
lower limit of around 200 nm. Therefore, smaller MPs, par-
ticularly exosomes, are below the detectability of these ma-
chines, and the fl uorescence data obtained from a given 
sample does not completely refl ect the full range of MP 
sizes observed by NTA and TRPS. Despite this, fl ow cytom-
etry is the most reliable technique to assess surface antigen 
expression of MPs. Importantly, NTA and TRPS confi rm 
that MPs within the range of 200–250 nm were reduced the 
most pre- versus post-apheresis, and are likely refl ected by 
the fl ow cytometric results. The use of annexin V positivity 
to identify MP populations is used widely ( 31, 46, 47 ), but 
has recently been questioned ( 48 ). As the majority (  90%) 
of MPs here were annexin V positive, we chose to accept this 
as our MP population for subsequent staining. Our ratio-
nale was based on the fact that despite not all MPs binding 
annexin V, only annexin V-positive MPs have been shown to 
possess procoagulant activity ( 48 ). 
 In summary, apheresis reduces the concentration of cir-
culating MPs in patients with FH, the majority of which are 
annexin V and platelet positive. Though MP concentra-
tion is reduced, apheresis has no effect on the total fatty 
acid concentration of MPs. Fatty acid composition of MPs 
is unique and does not refl ect that of the surrounding 
plasma. Each compartment is affected differently by apher-
esis, though the clinical relevance of this requires further 
investigation. MP concentration (particularly in the exo-
somal range) was found to positively correlate with total 
thrombin generation, suggesting that a reduction in MP 
concentration via apheresis in FH may reduce the ability 
of MPs to produce thrombin. The removal of MPs that are 
predominantly annexin V and platelet derived is a novel 
fi nding, supporting the notion that apheresis may have 
benefi cial cardiovascular effects beyond lipoprotein re-
moval. Future work should establish whether MP reduc-
tion during apheresis correlates with the longer-term ben-
efi ts of this treatment.  
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